89bio, Inc. (ETNB) Operating Income (Loss) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
89bio, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2024.
  • 89bio, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$57.3 M, a 101% decline year-over-year.
  • 89bio, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$180 M, a 70.3% decline year-over-year.
  • 89bio, Inc. annual Operating Income (Loss) for 2023 was -$151 M, a 47.9% decline from 2022.
  • 89bio, Inc. annual Operating Income (Loss) for 2022 was -$102 M, a 13.9% decline from 2021.
  • 89bio, Inc. annual Operating Income (Loss) for 2021 was -$89.7 M, a 81.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$180 M -$57.3 M -$28.8 M -101% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$151 M -$41.2 M -$15.8 M -62.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-01
Q3 2023 -$135 M -$39.3 M -$12.3 M -45.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$123 M -$42.1 M -$17.4 M -70.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 -$106 M -$28.5 M -$3.42 M -13.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$102 M -$25.4 M +$879 K +3.35% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-01
Q3 2022 -$103 M -$27 M +$1.17 M +4.15% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$104 M -$24.7 M -$4.19 M -20.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$100 M -$25.1 M -$10.4 M -70.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$89.7 M -$26.2 M -$13.7 M -109% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-01
Q3 2021 -$76 M -$28.2 M -$13.8 M -95.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$62.3 M -$20.6 M -$8.88 M -76.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$53.4 M -$14.7 M -$4.04 M -37.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$49.4 M -$12.5 M -$2.94 M -30.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 -$46.4 M -$14.4 M -$22.6 M -276% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$23.8 M -$11.7 M -$15.7 M -392% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$8.12 M -$10.7 M -$5.87 M -121% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$2.25 M -$9.61 M -$5.2 M -118% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-18
Q3 2019 $2.96 M $8.2 M +$12 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$9.03 M $4 M +$11 M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$20 M -$4.83 M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 -$4.41 M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-18
Q3 2018 -$3.79 M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-18
Q2 2018 -$6.97 M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.